Products and Services
-
Orbia Fluor & Energy Materials (previously Koura, Mexichem) has announced the submission of a drug master file for its HFA 152a MDI propellant, marketed as Zephex 152a. The company kicked off the transition to low global warming potential… Read more . . .
-
Chiesi and Inhalation CDMO Bespak have announced an expansion of an existing partnership to increase manufacturing capacity for LGWP propellant MDIs at Bespak’s Holmes Chapel, UK site. Chiesi announced plans to launch an HFA 152a inhaler by… Read more . . .
-
US-based CDMO Kenox Pharmaceuticals announced that it is now able to offer clinical manufacturing for OINDPs and has expanded its testing services for OINDPs, including in vitro BE. In January 2025, the company said that it… Read more . . .
-
Iconovo announced that it has signed a letter of intent with CDMO Lonza related to development of spray dried formulation of inhaled biologics. The companies announced in January 2025 that Lonza would develop spray dried… Read more . . .
-
Israeli psychedelic drug developer Clearmind Medicine has signed an agreement with Polyrizon for development of an intranasal formulation of Clearmind’s 5‑methoxy‑2‑aminoindane (MEAI) based on Polyrizon’s intranasal hydrogel technology, the companies said. According to Clearmind, MEAI… Read more . . .
-
Copley Scientific, which introduced its new dissolution testing apparatus for OINDPs at DDL 2025, has announced the official launch of the Inhaled Dissolution Apparatus (IDA). The company points out that many developers of generic inhaled… Read more . . .
-
According to DPI specialist Iconovo, the European Patent Office has indicated that it plans to approve the company’s patent application for the ICOpre inhaler platform. In 2024, the FDA indicated that the ICOpre device is… Read more . . .
-
US-based OINDP instrument and testing specialist Proveris Scientific has been acquired by Investindustrial, which describes itself as “one of Europe’s leading independent investment groups focused on taking majority or control positions, in quality leading mid-market companies.”… Read more . . .
-
CDMO Intertek announced that it has acquired a 29,000 sq ft facility in Melbourn, UK, which will allow the company to add to its GMP manufacturing capacity for inhaled drug products. The facility, which is… Read more . . .
-
US-based start-up CorriXR Therapeutics has announced a partnership with inhaled drug developer InhaTarget Therapeutics and device developer Merxin Ltd for development of an inhaled gene therapy for the treatment of lung cancer. InhaTarget will use its lipid… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden